New pneumococcal vaccine for routine childhood immunisation

Wyeth has launched Prevenar 13 for active immunisation against invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae.

On 19 January 2010, the Department of Health announced that Prevenar 13 would replace Prevenar in the routine childhood immunisation programme. Prevenar 13 is administered intramuscularly in the same dose schedule as Prevenar, but offers protection against 6 additional strains of S. pneumoniae (1, 3, 5, 6A, 7F and 19A).

Children who have already received 1 or 2 doses of 7-valent Prevenar should complete their vaccination course with Prevenar 13.

European serotype surveillance studies suggest that the new vaccine will protect against 73–100% of the pneumococcal strains that cause invasive disease in children under 5 years old.

View Prevenar 13 drug record

Further information: Wyeth

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more